Preempt future health risks.
Airfinity analysis shows Astrazeneca's monoclonal infant RSV drug could be administered to up to 3.5 million infants under one year of age in Europe once approved which would generate a potential revenue of up to $1.1bn.Read More →
Barron's | Sep 13, 2022Omicron boosters are a key milestone, but aren’t likely to woo new investors to Pfizer, Moderna
CNBC | Sep 7, 2022How nasal-spray vaccines could change the pandemic
Nature | Sep 6, 2022Airfinity estimates a shortage of up to 55 million monkeypox vaccine doses
Cinco Días | Aug 29, 2022
View All →
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
Market & Production
Disease & Prevalence
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,